You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Mitochondrial Antioxidant Neurodegenerative Therapeutics: XJB-5-131 Derivatives

    SBC: SOLANO PHARMACEUTICALS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Oxidative damage to mitochondrial is a major source of toxicity in diseases such as Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD). Mitochondria are energy powerhouses of the cell, and decline in their function by oxidative damage is a common feature among neurodegenerative diseases. Despite years of effort, however, generic ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers

    SBC: Protein Metrics Inc.            Topic: 300

    DESCRIPTION provided by applicant This project addresses the need for better methods for deciphering the glycosylation of proteins in clinical samples Glycosylation is an important modifier of protein structure and function and contributes to disease processes But we currently know little about the glycosylation of most proteins The current methods for probing glycans on proteins are not su ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

    SBC: SILVER LAKE RESEARCH CORPORATION            Topic: NIAID

    DESCRIPTION provided by applicant Bacterial resistance to lactam antibiotics is threatening to limit the effectiveness of this most used class of antibiotics A major contributin factor to this problem is the lack of rapid testing methods for medical practitioners to identify lactam resistant pathogens before prescribing specific antibiotics For urinary tract infections UTIs the most c ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Nitric Oxide Microfluidic Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Low-Cost Instrument-free Point-of-care Platform for Multiplexed Chlamydia Diagnos

    SBC: Lucira Health, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Detecting Chlamydia Ct STIs at the point of care POC represents a critical unmet medical need Development of an effective Ct POC diagnostic will result in widespread screening efforts for rapid diagnosis to inform treatment and evaluate treatment efficacy and for test of cure that would not only reduce the acute and chronic morbidity that is directly asso ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology

    SBC: Codagenix Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Antibody therapy for serious bacterial infections using polyclonal immune antitoxin or anti capsule horse serum actually predates small molecule antibiotic use However for reasons of safety convenient empirical use and cost the development of broader spectrum antibiotics rapidly supplanted the use of immune serum But drug resistance is quickly reducing th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A molecularly targeted pre- and post-exposure vaccine for anthrax

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant We have shown that immunization of rabbits with multiple antigenic peptides MAPs displaying sequence from domain of protective antigen PA elicit antibodies specific for a linear determinant within the loop of PA that mediate potent neutralization of lethal toxin LeTx in vitro We have now shown in two separate large studies that antibodies aga ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government